The removal of an entire Whitehall department is rarely viewed as positive for the firms that rely on it. The business community’s reaction to the decision to dissolve the Department for Science, Innovation and Technology has been sharply divided. Some express disappointment, while others welcome the return of a familiar face to the business brief.
Lord Vallance of Balham stepped down as science minister, and the department’s duties were merged into an expanded Department for Business and Trade. Jonathan Reynolds, who had previously served as business secretary, was reinstated ten months after being reassigned. The move signals a shift in focus toward a broader business agenda.
For life‑sciences small and medium‑sized enterprises, the reshuffle raises an immediate question: who will now champion science policy within the government? Vallance had been a key advocate for the sector, bridging industry and research.
Former president of research and development at GSK and former chief scientific adviser, Vallance left the post for personal reasons. His departure comes at a time when the life‑sciences sector is concerned about Britain’s declining position in global investment rankings. The sector has been awaiting a strong voice to guide its growth.
Industry leaders lament the loss of a minister who had helped improve the UK’s reputation as a life‑sciences destination. Vallance also played a role in launching the Health Data Research Service, a long‑promised initiative to open NHS data to medical researchers. His absence leaves a significant gap in leadership.
Companies are pressing the new administration to honour an agreement to double spending on innovative medicines over the next decade and to maintain a tariff exemption on pharmaceutical exports to the United States. A reversal would signal a negative shift in international perception. The sector is keen to see continuity in these commitments.
A life‑sciences investor expressed concern about being absorbed into a larger department, noting that while broader backing could be helpful, dilution among other priorities could be problematic. The sector’s focus on science and technology remains a key issue.
The wider business lobby is more optimistic, largely because of the return of Reynolds, who had overseen the industrial strategy that manufacturers broadly support. His familiarity with the strategy is seen as a positive sign for future policy direction.
The chief economist of the CBI highlighted Reynolds’ clear understanding of business challenges and his ability to act swiftly on the industrial strategy. The chief executive of Make UK stressed that success will be measured by lower costs, fewer trade barriers, and a more competitive environment for investment and export. The logistics sector views Reynolds’ return as a welcome development after a year of perceived lost opportunity.
For small and medium‑sized enterprises, the message is mixed but clear. A pro‑business stance from the top is welcome, yet science and technology firms will closely monitor whether their sector retains a strong voice within the restructured department. The outcome will shape the future of innovation and growth in the UK.
